The Lynx Group

Web Exclusives

Web Exclusives — November 16, 2019
On November 15, 2019, the FDA approved crizanlizumab (Adakveo; Novartis) to reduce the frequency of vaso-occlusive crises (VOCs) in adults and pediatric patients aged ≥16 years with sickle-cell disease.
Read Article




Web Exclusives — October 21, 2019
The past week in oncology-related news includes shortages of crucial pediatric cancer drug, results of a study of racial disparities in multiple myeloma, and new drug on the horizon for HER2 metastatic breast cancer.
Read Article

Web Exclusives — October 15, 2019
FDA issues finalized guidelines for use of in vitro diagnostics in oncology drug trials and warnings on vaping; new findings report patients bear more costs when MBC treatment is not concordant with NCCN guidelines.
Read Article

Web Exclusives — October 10, 2019
Leading healthcare industry expert, Dr Lee Newcomer, will deliver a keynote speech on Thursday, October 17. His talk, An Insider to Outsider’s Look at the Future of Cancer Care Delivery, begins at 8:15 am in the Lounge/Card Room, New York Athletic Club.
Read Article

Web Exclusives — September 27, 2019
On September 26, 2019, the FDA approved daratumumab (Darzalex; Janssen) in combination with bortezomib, thalidomide, and dexamethasone for the treatment of newly diagnosed patients with multiple myeloma who are eligible for autologous stem-cell transplant (ASCT). The FDA granted this application priority review.
Read Article

Web Exclusives — September 6, 2019
AVBCC is delighted to announce that John O’Brien, PharmD, MPH, former Senior Advisor to the Secretary, US Department of Health & Human Services (HHS), will present a Summit Keynote speech and Q&A at the 2019 AVBCC Summit on Thursday, October 17, in New York City.
Read Article


Page 4 of 9

Subscribe to
Value-Based Cancer Care

Stay up to date with personalized medicine by subscribing to recieve the free VBCC print publication or weekly e‑Newsletter.

I'd like to recieve: